Pixium Vision — Shareholder loan extends runway

Pixium Vision (PAR: PIX)

Last close As at 21/12/2024

EUR0.15

−0.04 (−21.05%)

Market capitalisation

EUR1m

More on this equity

Research: Healthcare

Pixium Vision — Shareholder loan extends runway

Pixium Vision recently announced that it has received a €3m bridge financing loan from shareholders Sofinnova (€1m) and Bpifrance (€2m), which extend its cash runway through to the end of November. The loan will bear interest at 12% pa and mature on 31 July 2024. The loan is a positive step and signal of confidence from these two institutional investors as Pixium works towards securing broader additional financing to bring it past the conclusion of the PRIMAvera European pivotal study, for which results are still anticipated in or around year-end 2023. We maintain our pipeline rNPV valuation of €140.1m but our equity valuation per pre-consolidation basic share is €0.90 (vs €0.92 previously) after adjusting for estimated H123 net debt.

Written by

Pooya Hemami

Analyst - Healthcare

Healthcare

Pixium Vision

Shareholder loan extends runway

Financing update

Healthcare equipment
and services

11 August 2023

Price

€0.06

Market cap

€9m

$1.10/€

Estimated net debt (€m) at 30 June 2023 excluding €0.8m in lease liabilities

5.9

Shares in issue (pre-consolidation)

149.0m

Free float

N/A

Code

ALPIX

Primary exchange

Euronext Growth Paris

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

(7.9)

(3.7)

(76.7)

Rel (local)

(11.4)

(4.6)

(79.2)

52-week high/low

€0.26

€0.03

Business description

Pixium Vision develops bionic vision systems for patients with severe vision loss. Its lead product, Prima, is a wireless subretinal implant system designed for dry age-related macular degeneration. The company completed implantations in Q422 for the PRIMAvera European pivotal study.

Next events

H123 financial results

September 2023

Analyst

Pooya Hemami, OD, MBA, CFA

+1 646 653 7026

Pixium Vision is a research client of Edison Investment Research Limited

Pixium Vision recently announced that it has received a €3m bridge financing loan from shareholders Sofinnova (€1m) and Bpifrance (€2m), which extend its cash runway through to the end of November. The loan will bear interest at 12% pa and mature on 31 July 2024. The loan is a positive step and signal of confidence from these two institutional investors as Pixium works towards securing broader additional financing to bring it past the conclusion of the PRIMAvera European pivotal study, for which results are still anticipated in or around year-end 2023. We maintain our pipeline rNPV valuation of €140.1m but our equity valuation per pre-consolidation basic share is €0.90 (vs €0.92 previously) after adjusting for estimated H123 net debt.

Year
end

Revenue
(€m)

PBT*
(€m)

EPS*
(€)

DPS
(€)

P/E
(x)

Yield
(%)

12/21

2.7

(10.9)

(0.23)

0.0

N/A

N/A

12/22

2.0

(10.3)

(0.21)

0.0

N/A

N/A

12/23e

1.8

(12.3)

(0.09)

0.0

N/A

N/A

12/24e

0.8

(13.0)

(0.09)

0.0

N/A

N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

PRIMAvera milestone expected near year-end 2023

Having completed the required 38 implantations in late 2022, PRIMAvera is assessing the safety and clinical benefits of the wireless Prima System in patients with geographic atrophy due to age-related macular degeneration (GA-AMD). We view the Prima System as a potentially transformative treatment in GA-AMD given the visual function improvements already shown in the earlier five-patient 36-month European feasibility study, including a median visual acuity among evaluable subjects improving from 20/500 pre-implantation to 20/71 (device-assisted with magnification). Prima also holds FDA Breakthrough Device designation, which suggests that the FDA recognises GA-AMD is an irreversibly debilitating human disease and that Prima System has the potential to provide an effective treatment. If PRIMAvera study results are positive, a CE Mark regulatory marketing submission can be filed in 2024, which could lead to commercialisation in H125.

Valuation: Mild revisions pre-consolidation

Pixium plans a 1 for 50 reverse stock split and shares are expected to trade on a post-consolidation basis on 21 September. The company reported a gross debt position of €10.3m at end-FY22 and, given the Q123 gross cash position of €4.7m, the c €2.4m in ESGO debt converted to equity in the year to date and the receipt of a €1.8m research tax credit (RTC) in June, we estimate €5.9m (H123) net debt. We have adjusted our estimates for the RTC and we now estimate a FY23 net operating burn rate of €16.1m (vs €17.6m previously). We maintain a pipeline rNPV valuation of €140.1m, resulting in an equity valuation of €134.2m after including net debt, or €0.90 per basic share (vs €0.92 previously), on a pre-consolidation basis. We assume Pixium will require €36m in funding to reach profitability (in FY25) and, if this need is met through equity issuances at the current market price (€0.057/share) and if outstanding ESGO debt (€1.25m) is also converted at this price, the resulting equity valuation would be €0.21 per share (pre-consolidation).

Exhibit 1: Financial summary

€000s

2018

2019

2020

2021

2022

2023e

2024e

31-December

IFRS

IFRS

IFRS

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

Revenue

 

 

1,598

1,782

2,092

2,655

1,955

1,800

800

Cost of Sales

(41)

0

0

0

0

0

0

General & Administrative

(2,019)

(3,572)

(4,008)

(5,084)

(4,650)

(5,398)

(6,628)

Research & Development

(5,297)

(6,563)

(5,704)

(7,282)

(8,793)

(7,800)

(4,500)

EBITDA

 

 

(5,758)

(8,352)

(7,620)

(9,712)

(11,488)

(11,398)

(10,328)

Depreciation

(677)

(448)

(366)

(549)

(456)

(277)

(226)

Amortization

0

0

0

0

0

0

0

Operating Profit (before exceptionals)

 

(6,435)

(8,801)

(7,986)

(10,261)

(11,944)

(11,675)

(10,554)

Exceptionals

(5,859)

(69)

(448)

0

0

0

0

Other

0

0

0

0

0

0

0

Operating Profit

(12,294)

(8,870)

(8,434)

(10,261)

(11,944)

(11,675)

(10,554)

Net Interest

(1,277)

(1,006)

(699)

(669)

1,632

(652)

(2,442)

Profit Before Tax (norm)

 

 

(7,712)

(9,806)

(8,685)

(10,930)

(10,312)

(12,328)

(12,996)

Profit Before Tax (FRS 3)

 

 

(13,571)

(9,876)

(9,133)

(10,930)

(10,312)

(12,328)

(12,996)

Tax

0

0

0

0

0

0

0

Profit After Tax and minority interests (norm)

(7,712)

(9,806)

(8,685)

(10,930)

(10,312)

(12,328)

(12,996)

Profit After Tax and minority interests (FRS 3)

(13,571)

(9,876)

(9,133)

(10,930)

(10,312)

(12,328)

(12,996)

Average Number of Shares Outstanding (m)

18.5

22.3

34.0

47.4

48.9

139.1

149.0

EPS - normalised (€)

 

 

(0.42)

(0.44)

(0.26)

(0.23)

(0.21)

(0.09)

(0.09)

EPS - normalised and fully diluted (€)

 

 

(0.42)

(0.44)

(0.26)

(0.23)

(0.21)

(0.09)

(0.09)

EPS - (IFRS) (€)

 

 

(0.73)

(0.44)

(0.27)

(0.23)

(0.21)

(0.09)

(0.09)

Dividend per share (€)

0.0

0.0

0.0

0.0

0.0

0.0

0.0

BALANCE SHEET

Fixed Assets

 

 

3,666

4,507

3,410

2,684

2,030

1,798

1,592

Intangible Assets

2,623

2,361

1,727

1,341

983

983

983

Tangible Assets

1,042

2,145

1,683

1,343

1,047

815

609

Current Assets

 

 

17,756

9,107

12,721

16,945

10,344

7,201

17,411

Short-term investments

0

0

0

0

0

0

0

Cash

15,629

6,792

10,566

14,505

7,687

4,544

14,667

Other

2,126

2,316

2,155

2,440

2,657

2,657

2,745

Current Liabilities

 

 

(2,044)

(2,880)

(3,885)

(6,483)

(8,698)

(4,651)

(4,651)

Creditors

(2,044)

(2,880)

(3,349)

(4,895)

(4,374)

(327)

(327)

Short term borrowings

0

0

(536)

(1,588)

(4,324)

(4,324)

(4,324)

Long Term Liabilities

 

 

(8,023)

(7,033)

(7,682)

(7,332)

(6,525)

(17,095)

(40,095)

Long term borrowings

(7,870)

(5,787)

(6,604)

(6,500)

(5,990)

(16,560)

(39,560)

Other long term liabilities

(153)

(1,246)

(1,078)

(832)

(535)

(535)

(535)

Net Assets

 

 

11,355

3,700

4,564

5,814

(2,849)

(12,748)

(25,743)

CASH FLOW

Operating Cash Flow

 

 

(6,174)

(7,282)

(6,207)

(8,160)

(12,960)

(15,445)

(10,415)

Net Interest

(1,277)

(1,006)

(699)

(669)

1,632

(652)

(2,442)

Tax

0

0

0

0

0

0

0

Net Operating Cash Flow

(7,450)

(8,288)

(6,906)

(8,829)

(11,328)

(16,097)

(12,857)

Capex

(31)

(34)

(82)

(48)

(92)

(45)

(20)

Acquisitions/disposals

0

0

0

0

0

0

0

Financing

14,068

2,034

9,055

13,170

(927)

2,430

0

Net Cash Flow

6,587

(6,288)

2,067

4,293

(12,347)

(13,712)

(12,877)

Opening net debt/(cash)

 

 

(1,401)

(7,760)

(1,004)

(3,426)

(6,417)

2,627

16,340

HP finance leases initiated

0

0

0

0

0

0

0

Other

(228)

(468)

354

(1,302)

3,303

0

0

Closing net debt/(cash)

 

 

(7,760)

(1,004)

(3,426)

(6,417)

2,627

16,339

29,217

Lease debt

na

1,346

1,258

1,045

765

765

765

Closing net debt/(cash) inclusive of IFRS16 lease debt

(7,760)

342

(2,168)

(5,372)

3,392

17,104

29,982

Source: Edison Investment Research, company accounts


General disclaimer and copyright

This report has been commissioned by Pixium Vision and prepared and issued by Edison, in consideration of a fee payable by Pixium Vision. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2023 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

General disclaimer and copyright

This report has been commissioned by Pixium Vision and prepared and issued by Edison, in consideration of a fee payable by Pixium Vision. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2023 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on Pixium Vision

View All

Latest from the Healthcare sector

View All Healthcare content

Research: Metals & Mining

Sylvania Platinum — Chrome ore and PGM treatment joint venture

Sylvania Platinum has announced a 50:50 joint venture (JV) with Limberg Mining Company to process platinum group metals (PGM) and chrome ores from Limberg’s historical tailings dumps and run-of-mine ore. The mine, located in the northern part of the western limb of the Bushveld Complex, will start producing from H225, could add to Sylvania’s production and will diversify its resource mix to include chrome concentrate. Sylvania is investing $32m in capital expenditure (of which 50% will be paid back by Limberg from JV cash flow after the start of production) and $5m in working capital from its large cash resources in exchange for c 6,500koz of forecast PGM and 200kt of chrome concentrate production. Management is forecasting an internal rate of return more than Sylvania’s minimum requirement of 20% pa and a three-year cash payback. Our forecasts and valuation are under review.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free